Hypogonadism Market

Market Overview:

The 7 major hypogonadism markets reached a value of US$ 6.6 Billion in 2023. Looking forward, IMARC Group expects the 7MM to reach US$ 9.6 Billion by 2034, exhibiting a growth rate (CAGR) of 3.43% during 2024-2034.

The hypogonadism market has been comprehensively analyzed in IMARC's new report titled "Hypogonadism Market: Epidemiology, Industry Trends, Share, Size, Growth, Opportunity, and Forecast 2024-2034". Hypogonadism is a medical disorder that occurs when the body doesn't produce enough sex hormones responsible for the development of sexual characteristics and the regulation of reproductive functions. In children, this condition manifests as a lack of growth and development at the standard age for puberty, incomplete formation of sexual attributes, short stature, inability to smell, etc. Some of the common symptoms of hypogonadism in males include decreased sex drive, erectile dysfunction, infertility, lowered muscle mass, reduced facial or body hair, etc. In females, hypogonadism may cause irregular periods, infertility, hot flashes, a relatively low sexual drive, etc. The healthcare provider may review the patient's symptoms and medical history and perform a physical exam to establish a diagnosis. Several common laboratory tests and procedures, such as genetic testing, blood workup, pelvic ultrasound, etc., are also utilized to confirm the disease. Additionally, an MRI of the pituitary gland or hypothalamus can be required to visualize a tumor or other abnormal growth in the patients.

The increasing prevalence of testis and ovary disorders caused by genetic defects, injury, infection, radiation or chemotherapy, autoimmune diseases, etc., is primarily driving the hypogonadism market. In addition to this, the rising incidence of several risk factors, such as pituitary or hypothalamic tumors, head trauma, obesity, chronic illnesses, excessive alcohol consumption, smoking, etc., is also propelling the market growth. Furthermore, the inflating adoption of effective medications, including selective estrogen receptor modulators (SERMs) and selective androgen receptor modulators (SARMs), to help direct the development of sexual features and lessen the symptoms of the ailment, is acting as another significant growth-inducing factor. Apart from this, the escalating application of hormone replacement therapy for restoring hormone levels to the normal physiological range and combating the effects of the underlying condition is also creating a positive outlook for the market. Additionally, the emerging popularity of subcutaneous hormone pellet implant, which offers a hassle-free treatment alternative to provide sustained and steady testosterone and/or estradiol levels, is expected to drive the hypogonadism market in the coming years.  

IMARC Group's new report provides an exhaustive analysis of the hypogonadism market in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan. This includes treatment practices, in-market, and pipeline drugs, share of individual therapies, market performance across the seven major markets, market performance of key companies and their drugs, etc. The report also provides the current and future patient pool across the seven major markets. According to the report the United States has the largest patient pool for hypogonadism and also represents the largest market for its treatment. Furthermore, the current treatment practice/algorithm, market drivers, challenges, opportunities, reimbursement scenario and unmet medical needs, etc. have also been provided in the report. This report is a must-read for manufacturers, investors, business strategists, researchers, consultants, and all those who have any kind of stake or are planning to foray into the hypogonadism market in any manner.

Time Period of the Study

• Base Year: 2023
• Historical Period: 2018-2023
• Market Forecast: 2024-2034
   

Countries Covered

• United States
• Germany
• France
• United Kingdom
• Italy
• Spain
• Japan
   

Analysis Covered Across Each Country

• Historical, current, and future epidemiology scenario
• Historical, current, and future performance of the hypogonadism market
• Historical, current, and future performance of various therapeutic categories in the market
• Sales of various drugs across the hypogonadism market
• Reimbursement scenario in the market
• In-market and pipeline drugs

Competitive Landscape:

This report also provides a detailed analysis of the current hypogonadism marketed drugs and late-stage pipeline drugs.

In-Market Drugs

• Drug Overview
• Mechanism of Action
• Regulatory Status
• Clinical Trial Results
• Drug Uptake and Market Performance    
   

Late-Stage Pipeline Drugs

• Drug Overview
• Mechanism of Action
• Regulatory Status
• Clinical Trial Results
• Drug Uptake and Market Performance
   

*Kindly note that the drugs in the above table only represent a partial list of marketed/pipeline drugs, and the complete list has been provided in the report.

Key Questions Answered in this Report:

Market Insights

• How has the hypogonadism market performed so far and how will it perform in the coming years?
• What are the markets shares of various therapeutic segments in 2023 and how are they expected to perform till 2034?
• What was the country-wise size of the hypogonadism market across the seven major markets in 2023 and what will it look like in 2034?
• What is the growth rate of the hypogonadism market across the seven major markets and what will be the expected growth over the next ten years?
• What are the key unmet needs in the market?
   

Epidemiology Insights

• What is the number of prevalent cases (​2018-2034​) of hypogonadism across the seven major markets?
• What is the number of prevalent cases (​2018-2034​) of hypogonadism by age across the seven major markets?
• What is the number of prevalent cases (​2018-2034​) of hypogonadism by gender across the seven major markets?
• What is the number of prevalent cases (​2018-2034​) of hypogonadism by type across the seven major markets?
• How many patients are diagnosed (​2018-2034​) with hypogonadism across the seven major markets?
• What is the size of the hypogonadism patient pool (2018-2023) across the seven major markets?
• What would be the forecasted patient pool (2024-2034) across the seven major markets?
• What are the key factors driving the epidemiological trend of hypogonadism?
• What will be the growth rate of patients across the seven major markets?
   

Hypogonadism: Current Treatment Scenario, Marketed Drugs and Emerging Therapies

• What are the current marketed drugs and what are their market performance?
• What are the key pipeline drugs and how are they expected to perform in the coming years?
• How safe are the current marketed drugs and what are their efficacies?
• How safe are the late-stage pipeline drugs and what are their efficacies?
• What are the current treatment guidelines for hypogonadism drugs across the seven major markets?
• Who are the key companies in the market and what are their market shares?
• What are the key mergers and acquisitions, licensing activities, collaborations, etc. related to the hypogonadism market?
• What are the key regulatory events related to the hypogonadism market?
• What is the structure of clinical trial landscape by status related to the hypogonadism market?
• What is the structure of clinical trial landscape by phase related to the hypogonadism market?
• What is the structure of clinical trial landscape by route of administration related to the hypogonadism market?